Literature DB >> 15352059

Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity.

Naoko Yamane-Ohnuki1, Satoko Kinoshita, Miho Inoue-Urakubo, Machi Kusunoki, Shigeru Iida, Ryosuke Nakano, Masako Wakitani, Rinpei Niwa, Mikiko Sakurada, Kazuhisa Uchida, Kenya Shitara, Mitsuo Satoh.   

Abstract

To generate industrially applicable new host cell lines for antibody production with optimizing antibody-dependent cellular cytotoxicity (ADCC) we disrupted both FUT8 alleles in a Chinese hamster ovary (CHO)/DG44 cell line by sequential homologous recombination. FUT8 encodes an alpha-1,6-fucosyltransferase that catalyzes the transfer of fucose from GDP-fucose to N-acetylglucosamine (GlcNAc) in an alpha-1,6 linkage. FUT8(-/-) cell lines have morphology and growth kinetics similar to those of the parent, and produce completely defucosylated recombinant antibodies. FUT8(-/-)-produced chimeric anti-CD20 IgG1 shows the same level of antigen-binding activity and complement-dependent cytotoxicity (CDC) as the FUT8(+/+)-produced, comparable antibody, Rituxan. In contrast, FUT8(-/-)-produced anti-CD20 IgG1 strongly binds to human Fcgamma-receptor IIIa (FcgammaRIIIa) and dramatically enhances ADCC to approximately 100-fold that of Rituxan. Our results demonstrate that FUT8(-/-) cells are ideal host cell lines to stably produce completely defucosylated high-ADCC antibodies with fixed quality and efficacy for therapeutic use.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15352059     DOI: 10.1002/bit.20151

Source DB:  PubMed          Journal:  Biotechnol Bioeng        ISSN: 0006-3592            Impact factor:   4.530


  150 in total

1.  Quantitative evaluation of fucose reducing effects in a humanized antibody on Fcγ receptor binding and antibody-dependent cell-mediated cytotoxicity activities.

Authors:  Shan Chung; Valerie Quarmby; Xiaoying Gao; Yong Ying; Linda Lin; Chae Reed; Chris Fong; Wendy Lau; Zhihua J Qiu; Amy Shen; Martin Vanderlaan; An Song
Journal:  MAbs       Date:  2012-04-26       Impact factor: 5.857

Review 2.  Research and development of next generation of antibody-based therapeutics.

Authors:  Jing Li; Zhenping Zhu
Journal:  Acta Pharmacol Sin       Date:  2010-08-09       Impact factor: 6.150

3.  Engineering of Yeast Glycoprotein Expression.

Authors:  Charlot De Wachter; Linde Van Landuyt; Nico Callewaert
Journal:  Adv Biochem Eng Biotechnol       Date:  2021       Impact factor: 2.635

4.  Chemoenzymatic synthesis and Fcγ receptor binding of homogeneous glycoforms of antibody Fc domain. Presence of a bisecting sugar moiety enhances the affinity of Fc to FcγIIIa receptor.

Authors:  Guozhang Zou; Hirofumi Ochiai; Wei Huang; Qiang Yang; Cishan Li; Lai-Xi Wang
Journal:  J Am Chem Soc       Date:  2011-11-01       Impact factor: 15.419

Review 5.  Therapeutic antibodies: successes, limitations and hopes for the future.

Authors:  Patrick Chames; Marc Van Regenmortel; Etienne Weiss; Daniel Baty
Journal:  Br J Pharmacol       Date:  2009-05       Impact factor: 8.739

6.  Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors.

Authors:  Stephen L Sazinsky; René G Ott; Nathaniel W Silver; Bruce Tidor; Jeffrey V Ravetch; K Dane Wittrup
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-12       Impact factor: 11.205

Review 7.  Targeting the Fc receptor in autoimmune disease.

Authors:  Xinrui Li; Robert P Kimberly
Journal:  Expert Opin Ther Targets       Date:  2014-03       Impact factor: 6.902

Review 8.  Chemoenzymatic Methods for the Synthesis of Glycoproteins.

Authors:  Chao Li; Lai-Xi Wang
Journal:  Chem Rev       Date:  2018-08-24       Impact factor: 60.622

9.  Antitumor Efficacy of Anti-GD2 IgG1 Is Enhanced by Fc Glyco-Engineering.

Authors:  Hong Xu; Hongfen Guo; Irene Y Cheung; Nai-Kong V Cheung
Journal:  Cancer Immunol Res       Date:  2016-05-16       Impact factor: 11.151

10.  The GalNAc-type O-Glycoproteome of CHO cells characterized by the SimpleCell strategy.

Authors:  Zhang Yang; Adnan Halim; Yoshiki Narimatsu; Hiren Jitendra Joshi; Catharina Steentoft; Katrine Ter-Borch Gram Schjoldager; Morten Alder Schulz; Natalie R Sealover; Kevin J Kayser; Eric Paul Bennett; Steven B Levery; Sergey Y Vakhrushev; Henrik Clausen
Journal:  Mol Cell Proteomics       Date:  2014-08-04       Impact factor: 5.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.